Zoetis (ZTS) Stock Price & Analysis

ZTS$83.82+0.86 +1.04%
Drug Manufacturers - Specialty & GenericLarge CapValue StockHigh Quality
Compare
Market cap$34.06BEnterprise value$41.96BRevenue (TTM)$9.51BMarket positionTop 25%

Score

62
Neutral
Value
67
Quality
80
Growth
38

AI Analysis

Snapshot

Zoetis reads as an income name — Stocklytics 62/100, with a 2.5% dividend yield in the thesis. Under the hood: P/E 14.2, about 63% below its own multi-year median, plus revenue compounding ~5% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

67
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

38
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

80
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Zoetis Inc. (ZTS) last printed $83.82. Equity value is $34.06B. Trailing earnings multiple 13.02. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$4.89B$5.31B$5.83B$6.26B$6.67B$7.78B$8.08B$8.54B$9.26B$9.47B

About

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Zoetis (ZTS) Stock Price & Analysis

ZTS price $83.82 +0.86 +1.04%

Ticker
ZTS
Price
$83.82
Change
+0.86 +1.04%
Market cap
$34.06B
P/E
13.02
Forward P/E
13.56
Dividend yield
2.53%
Beta
0.68
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stocklytics score
62
Value
67
Quality
80
Growth
38

Stocklytics score rationale: value 67, quality 80, growth 38.

AI Score 75. Zoetis Inc. has a solid market capitalization of approximately $36.8 billion and a stable price of $89.17, reflecting a price-to-earnings ratio of about 14.7

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener